{"disease":{"id":"autologous-stem-cell-transplant","name":"autologous stem cell transplant"},"drugs":{"marketed":[{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Autologous Stem Cell Transplantation for the Treatment of HIV","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"busilvex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"busulfan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"busulfex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulphan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02181413","title":"A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":656,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05835726","title":"Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.","phase":"","overall_status":"COMPLETED","enrollment_count":188,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03429387","title":"PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia","phase":"NA","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"Peter MacCallum Cancer Centre, Australia","has_results":false},{"nct_id":"NCT05814718","title":"Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT","phase":"NA","overall_status":"UNKNOWN","enrollment_count":122,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT05218603","title":"Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT06381830","title":"Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03238599","title":"Pedometer Activity Monitoring After ASCT","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT04464434","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT05087212","title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05681403","title":"Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":53,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT04653246","title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Jacob Laubach, MD","has_results":false},{"nct_id":"NCT04364256","title":"Muscle Stimulation for Physical Function During Stem Cell Transplant","phase":"NA","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06818916","title":"Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Beijing Children's Hospital","has_results":false},{"nct_id":"NCT04783038","title":"Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06377540","title":"MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT04194840","title":"Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06931613","title":"Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT01163357","title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07458854","title":"Exercise in Patients Undergoing Autologous Stem Cell Transplantation: A Randomized Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"TC Erciyes University","has_results":false},{"nct_id":"NCT05524688","title":"Beta-glucan and Fatigue in HSCT Survivors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"University of Florida","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}